RecruitingPhase 2NCT03392233

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors

A Phase II Study to Evaluated the Long-term of Safety and Efficacy of Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors


Sponsor

RenJi Hospital

Enrollment

100 participants

Start Date

Aug 18, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Stereotactic Body Radiation Therapy(SBRT) for spinal metastases has been proved a good results in pain relieve and local control, However,the longterm of efficacy and safety of this regimen is unclear.The purpose of the study is to evaluate the longterm outcome of this therapeutic regimen in selective patients who will be survival more than 2 years.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Inclusion Criteria16

  • WHO scores 0-2;
  • The primary lesion was confirmed by pathology or cytology;
  • The metastatic lesions were diagnosed by imaging(CT,MRI,PET-CT,ECT),or the lesions were confirmed by biopsy;
  • The metastatic lesion was limited in 3 consecutive vertebral bodies;
  • The baseline pain score was ≥5(NRPS) and the use of analgesic drugs was recorded;
  • The enhanced MRI scan of involved vertebral bodies was required in the 2 weeks before radiotherapy;
  • Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment:
  • Leukocytes ≥ 3.0 x109/ L;
  • Absolute neutrophil count (ANC) ≥ 1.5 x109/ L;
  • Platelet count ≥ 100 x109/ L;
  • Hemoglobin (Hb) ≥ 9g/ dL;
  • Total bilirubin ≤1.5 x the upper limit of normal (ULN);
  • Alanine aminotransferase (ALT) ≤ 3 x ULN;
  • Aspartate aminotransferase (AST) ≤ 3 x ULN;
  • Serum creatinine ≤ 1.5 x the ULN;
  • Signed informed consent;

Exclusion Criteria8

  • There were significant changes in the shape of the vertebral body (the height of the vertebral body was compressed≥ 50%) or the vertebral body was unchanged but the volume of the dissolving bone was≥ 50% and could lead to serious bone adverse events;
  • There were \>3 consecutive vertebral bodies involved;
  • Spinal cord compression has occurred;
  • The gap between tumor and spinal cord was less than 3mm;
  • The metastatic area previously received radiation;
  • Pregnant and Nursing women;
  • Uncontrolled co-morbid illnesses;
  • refused to signed informed consent;

Interventions

RADIATIONStereotactic Body Radiation Therapy

Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time


Locations(1)

Department of Radiation Oncology,Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03392233


Related Trials